Overweight patients more likely to experience recurrent atrial fibrillation after ablation

Overweight patients with atrial fibrillation are more likely to experience a return of the heart rhythm disorder after a corrective procedure than those of normal weight, according to research presented at EHRA 2022, a scientific congress of the European Society of Cardiology (ESC).

The risk of recurrent atrial fibrillation after ablation rose incrementally as body mass index (BMI) increased. Our study suggests that overweight patients should be advised to lose weight before the intervention to improve the likelihood of being free of the arrhythmia afterwards."

Dr. Jacob Toennesen, Lead Author, Gentofte University Hospital, Denmark

Atrial fibrillation is the most common heart rhythm disorder worldwide. It is estimated that one in three Europeans will develop the condition. Atrial fibrillation is associated with elevated risks of stroke, heart failure and premature death, while more than 60% of patients have impaired quality of life. Dr. Toennesen said: "The potential for deleterious outcomes means that obtaining a normal heart rhythm is a crucial goal of treatment."

Treatment options include drugs and ablation, which involves burning or freezing a small portion of the heart to create a scar and prevent the spread of abnormal electrical impulses. While previous research has shown that obesity is associated with the development of atrial fibrillation, this study examined the link between BMI and a return of the heart rhythm disorder after ablation.

The study was conducted using Danish nationwide registries. It included a total of 9,229 adults who underwent a first-time atrial fibrillation from 2010 through 2018. Patients were divided into five groups according to BMI in kg/m2: underweight (below 18.5), normal weight (18.5 to 24), overweight (25 to 29), obese (30 to 34) and morbidly obese (over 34). The median age decreased from 64 years in the normal weight group to 60 years in the morbidly obese group.

Patients were deemed to have experienced atrial fibrillation during follow-up if they claimed prescriptions of anti-arrhythmic drugs, were hospitalised due to atrial fibrillation, underwent re-ablation, or had an electrical cardioversion which transmits electric shocks to the heart through electrodes on the chest to restore normal heart rhythm.

The authors analyzed the relative risk of recurrent atrial fibrillation according to BMI after adjusting for sex, age, procedure year, heart failure, ischaemic heart disease, chronic obstructive pulmonary disease (COPD), chronic kidney disease, hypertension and diabetes. At one year, compared to the normal weight group, the overweight, obese and morbidly obese groups had a 19%, 22% and 32% higher likelihood of atrial fibrillation, respectively. The same pattern was observed after five years, with 15%, 18% and 26% higher risks of the abnormal heart rhythm in the overweight, obese and morbidly obese groups, respectively, compared with the normal weight group. The relative risk in underweight patients did not significantly differ from those with normal weight at either time point.

Dr. Toennesen said: "The study shows that recurrence rates of atrial fibrillation increased incrementally with rising BMI at short- and long-term follow-up. For instance, after one year 61% of normal weight patients were still free of the heart rhythm disorder compared to just 52% of morbidly obese patients. We also observed that both procedure duration and X-ray dose increased with rising BMI."

He concluded: "The strength of association between high BMI and repeat atrial fibrillation after ablation was comparable to the influence of well-known factors like heart failure, COPD and hypertension which are typically treated in these patients. The findings indicate that aggressive weight management prior to ablation could potentially lead to better outcomes."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New PREVENT risk equations could reduce statin use by 40%, study finds